Multiple sclerosis - In need of a critical reappraisal

Medical Hypotheses

Volumn 54, Issue 1, 2000, Pages 99-106

  Steiner, I ^a   Wirguin, I ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; COPAXON; GLATIRAMER; INTERFERON BETA SERINE; UNCLASSIFIED DRUG;

DISEASE CLASSIFICATION; HUMAN; MULTIPLE SCLEROSIS; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT;

EID: 0034013558     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1998.0835     Document Type: Article

References (76)

1. Schumacher G. A., Beebe G., Kubler R. F. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci. 122:1965;522-568.
2. Rao S. M., Hammeka T. A., McQuillen M. P., Khatri B. O., Lloyd D. Memory disturbances in chronic progressive multiple sclerosis. Arch Neurol. 41:1984;625-631.
3. Huber S. J., Paulson G. W., Shuttleworth E. C. Magnetic resonance imaging correlates of dementia in multiple sclerosis. Arch Neurol. 44:1987;732-736.
4. Whitlock F. A., Siskind M. M. Depression as a major symptom of multiple sclerosis. J Neurol Neurosurg Psychiatry. 43:1980;861-865.
5. Matthews W. B. Tonic seizures in disseminated sclerosis. Brain. 81:1958;193-206.
6. Heath P. D., Nightingale S. Clusters of tonic spasms as an initial manifestation of multiple sclerosis. Ann Neurol. 12:1986;494-495.
7. Pollock M., Calder C., Allpers S. Peripheral nerve abnormality in multiple sclerosis. Ann Neurol. 2:1977;41-48.
8. Argyrakis A. Ultrastructural changes in peripheral nerves in multiple sclerosis and subacute sclerosing panencephalitis. Bauer H. J., Poser S. M., Ritter G. Progress in Multiple Sclerosis Research. 1980;360-364 Springer Verlag, Berlin.
9. Eisen A., Paty D., Horich M. Altered supernormality in multiple sclerosis peripheral nerve. Muscle Nerve. 5:1982;411-414.
10. Zee P. C., Cohen B. A., Walczak T., Jubelt B. Peripheral nervous system involvement in multiple sclerosis. Neurology. 41:1991;457-460.
11. Berger J. R., Sheremata W. A., Melamed E. Paroxysmal dystonia as the initial manifestation of multiple sclerosis. Arch Neurol. 41:1984;747-750.
12. Miller A. E. Clinical features. Cook S. D. Handbook of Multiple Sclerosis. 1990;169-186 Marcel Decker, New York.
13. Brisman R. Trigeminal neuralgia in multiple sclerosis. Arch Neurol. 44:1987;379-381.
14. Brandt S., Glydensted C., Offner H., Melchior J. C. Multiple sclerosis with onset in a two-year old boy. Neuropediatrics. 12:1981;75-82.
15. Hauser S. L., Bresman M. J., Reinherz E. L., Weiner H. L. Childhood multiple sclerosis: clinical features and demonstration of changes in T cell subsets with disease activity. Ann Neurol. 11:1982;463-468.
16. Shaw C. M., Alvord E. C. Multiple sclerosis beginning in infancy. J Child Neurol. 2:1987;252-256.
17. Poser C. M., Paty D. W., Scheinberg L. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 13:1983;277-231.
18. McDonald W. I., Silberberg D. H. The diagnosis of multiple sclerosis. McDonald W. I., Silberberg D. H. Multiple Sclerosis. 1986;1-10 Butterworths, London.
19. Neurology. 43:1993;655-661.
20. Paty D. W., Li D. K. B. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized double-blind placebo-controlled trial. Neurology. 43:1993;662-667.
21. Neurology. 45:1995;1277-1285.
22. Johnson K. P., Brooks B. R., Cohen J. A. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 45:1995;1268-1276.
23. Wolinsky J. S. Copolymer 1: A most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability. Neurology. 45:1995;1245-1247.
24. Weinshenker B. G., Sibley W. A. Natural history and treatment of multiple sclerosis. Curr Opin Neurol Neurosurg. 5:1992;203-211.
25. Jacobs L. D., Cookfair D. L., Rudick R. A. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 39:1996;285-294.
26. Stone L. A., Smith M. E., Albert P. S. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis. Relationship to course, gender and age. Neurology. 45:1995;1122-1126.
27. Miller D. H., Albert P. S., Barkhof F. Guidelines for the use of magnetic resonance technique in monitoring the treatment of multiple sclerosis. Ann Neurol. 39:1996;6-16.
28. Phadke J. G., Best P. V. Atypical and clinically silent multiple sclerosis: a report of 12 cases discovered unexpectedly at necroscopy. J Neurol Neurosurg Psychiatry. 46:1983;4141-4420.
29. Gilbert J. J., Sadler M. Unsuspected multiple sclerosis. Arch Neurol. 40:1983;533-536.
30. Morariu M., Klutzow W. F. Subclinical multiple sclerosis. J Neurol. 213:1976;71-76.
31. Marburg O. Die sogenannte 'akute multiple Sklerose' (encephalomyelitis periaxialis scleroticans). Jahrbucher für Psychiatrie und Neurologie (Leipzig). 27:1906;213-311.
32. Harper C. G. Acute central nervous system disorder mimicking stroke. Med J Aust. 1:1981;136-138.
33. Prineas, J. W. Pathology of multiple sclerosis, Cook, S. D. Handbook of Multiple Sclerosis, Marcel Decker, New York, 1990, 187, 218.
34. Peress N. S., Siegelman J., Fleit H. B. High avidity periventricular IgG-Fc receptor activity in human and rabbit brain. Clin Immunol Immunopathol. 42:1987;229-238.
35. Oppenheimer D. R. The cervical cord in multiple sclerosis. Neuropath Appl Neurobiol. 4:1978;151-162.
36. Lumsden C. E. The neuropathology of multiple sclerosis. Vinken P. J., Bruyn G. W. Handbook of Clinical Neurology. 1970;217-309.
37. Weller R. O. Pathology of multiple sclerosis. Mathews W. B. McAlpine's Multiple Sclerosis. 1985;301-343 Churchill Livingstone, Edinburgh.
38. Revesz T., Kidd D., Thompson A. J., Barnard R. O., McDonald W. I. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 117:1994;759-765.
39. Ozawa K., Suchanek G., Breitschopf H. Patterns of oligodendroglia pathology in multiple sclerosis. Brain. 117:1994;1311-1322.
40. Sobel R. A. The pathology of multiple sclerosis. Neurol Clin. 13:1995;1-21.
41. Schoene W. C., Carpenter S., Behan P. O., Geschwind N. Onion bulb formation in the central and peripheral nervous system in association with multiple sclerosis and hypertrophic polyneuropathy. Brain. 100:1977;755-773.
42. Miller D. H. Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol. 36:1994;S91-S94.
43. Miller D. H. Magnetic resonance imaging and spectroscopy in multiple sclerosis. Curr Opin Neurol. 8:1995;210-215.
44. Matthews P. M., Pioro E., Narayanan S. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain. 119:1996;715-722.
45. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 85:1996;299-302.
46. Ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet. 343:1994;271-275.
47. Bansil S., Cook S. D., Rohowsky-Kochan C. Multiple sclerosis: immune mechanisms and update on current therapies. Ann Neurol. 37:1995;S87-S101.
48. Dal Canto, M. C. Experimental models of virus-induced demyelination, Cook, S. D. Handbook of Multiple Sclerosis, Marcel Decker, New York, 1990, 63, 100.
49. Kennedy P. G. E., Steiner I. The possible viral etiology of multiple sclerosis. Qu J Med. 87:1994;523-528.
50. Gilden D. H., Devlin M. E., Burgoon M. P., Owens G. P. The search for visus in multiple sclerosis. Mult Scler. 2:1966;179-183.
51. Kies M. W. Species specificity and localization of encephalitogenic sites in myelin basic protein. Steck A. J., Lisak R. P. Immunoneurology. 1985;295-304 Springer Verlag, New York.
52. Swanborg R. H. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin Immunol Immunopathol. 77:1995;4-13.
53. Rivers T. M., Sprunt D. H., Berry G. P. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med. 58:1933;39-53.
54. Raine C. S., Traugott U. Immunopathology of the lesion in multiple sclerosis and chronic relapsing experimental allergic encephalomyelitis. Vandenbark A. A., Raus J. C.M. Immunoregulatory Processes in Experimental Allergic Encephalomyelitis and Multiple Sclerosis. 1984;125-150 Elsevier, Amsterdam.
55. Lublin, F. D. Relapsing experimental allergic encephalomyelitis - an autoimmune model of multiple sclerosis, Steck, A. J.Lisak, R. P. Immunoneurology, Springer Verlag, New York, 1985, 8, 197, 208.
56. Lisak R. P. Overview of the rational for immunomodulating therapies in multiple sclerosis. Neurology. 38:1988;5-8.
57. Khoury S. J., Weiner H. L., Hafler D. A. Immunologic basis of multiple sclerosis. Cook S. D. Handbook of Multiple Sclerosis. 1990;187-218 Marcel Decker, New York.
58. Smith D. R., Weiner H. L. Immunologic aspects of neurologic and neuromuscular diseases. JAMA. 278:1997;1956-1961.
59. Cook S. D. Handbook of Multiple Sclerosis. 1990;Marcel Decker, New York.
60. Ebers G. C. Treatment of multiple sclerosis. Lancet. 343:1994;275-279.
61. Lewis R. A., Selwa J. F., Lisak R. P. Myasthenia gravis: immunological mechanism and immunotherapy. Ann Neurol. 37:1995;S51-S62.
62. Lhote F., Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Clinical Aspects and treatment. Rheum Dis Clin North Am. 21:1995;911-947.
63. Miller H. G., Gibbons J. L. Acute disseminated encephalomyelitis and acute disseminated sclerosis: results of treatment with ACTH. BMJ. 2:1953;1345-1349.
64. Miller H., Newell D. J., Ridley A. Multiple sclerosis: treatment of acute exacerbations with cortictropin (ACTH). Lancet. 2:1961;1120-1122.
65. Zamwil S. S., Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol. 8:1990;579-621.
66. Saeki Y., Mima T., Sakoda S. Transfer of multiple sclerosis into severe combined immunodeficiency mice by mononuclear cells from cerebrospinal fluid of the patients. Proc Natl Acad Sci USA. 89:1992;6157-6161.
67. Hao Q., Saida T., Nishimura M., Ozawa K., Saida K. Failure to transfer multiple sclerosis into severe combined immunodeficiency mice by mononuclear cells from CSF of patients. Neurology. 44:1994;163-165.
68. Jeffery D. R., Alshami E. Allogenic bone marrow transplantation in multiple sclerosis. Neurology. 50:1998;A147.
69. Gonzales-Scarano F., Spielman R. S., Nathanson N. Epidemiology. McDonald W. I., Silberberg D. H. Multiple Sclerosis. 1986;37-55 Butterworths, London.
70. Hauser S. L. Multiple sclerosis and other demyelinating diseases. Isselbacher. Harrison's Principles of Internal Medicine. 1994;2287-2295.
71. The Wall Street Journal. December 19, 1996.
72. Kessler D. A., Feiden K. L. Faster evaluation of vital drugs. Sci Am. 272:1995;26-33.
73. Mervis J. Clinton holds the line on R&D. Science. 267:1995;780-782.
74. Blumental D., Causino N., Campbell E., Seashore K. Relationship between academic institutions and industry in the life sciences - an industry survey. N Engl J Med. 334:1996;368-373.
75. Marshall E. Gene therapy's growing pains. Science. 269:1995;1050-1055.
76. Daroff R. B. Editorials in scientific publications. Neurology. 46:1966;883.